問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Neurology

更新時間:2023-09-19

盧菁華Lu, Ching-Hua Lu
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -3 個月

篩選

List

40Cases

2025-02-01 - 2027-12-31

Phase II

Completed
A randomized, blinded, placebo-controlled phase 2 trial evaluating the safety, tolerability, quantitative pharmacology, and efficacy (MAGIC) of DNTH103 in adult patients with generalized myasthenia gravis.
  • Condition/Disease

    ● Evaluate the safety and tolerability of DNTH103 in patients with generalized myasthenia gravis (gMG) up to week 13.

  • Test Drug

    DNTH103 150 mg/mL

Participate Sites
8Sites

Recruiting8Sites

2026-08-01 - 2035-12-31

Phase III

Not yet recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    注射液劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-09-01 - 2028-12-31

Phase II

Not yet recruiting
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer's Disease
  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    錠劑

Participate Sites
9Sites

Not yet recruiting9Sites

2020-12-01 - 2022-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2018-06-01 - 2023-03-21

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated6Sites

2021-02-01 - 2027-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-09-15 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-07-01 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-12-01 - 2028-01-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-03-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

1 2 3 4